Upcoming Financial Announcement and Conference Details
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) is set to disclose its financial performance for the second quarter of 2025 following the market closure. This announcement will be made on a Thursday, marking a significant moment as the company continues to make strides in the medical device field.
The management team at Profound looks forward to engaging with stakeholders during a scheduled conference call at 4:30 p.m. ET where they will provide a detailed analysis of the financial results and discuss the latest business developments.
What to Expect from the Q2 2025 Conference Call
This essential call will not only cover the financial results, but it will also serve as a platform for the management to elaborate on strategic updates and future initiatives. The call will be available live, and investors can access an archived version on Profound's official website under the Investor section.
To register for the live call, be sure to mark your calendars. Engaging with the management team during this period can provide valuable insights into the company's direction.
About Profound Medical Corp.
Profound is a pioneering medical device company specializing in non-invasive, customizable therapies aimed at the ablation of diseased tissue. At the forefront of their offerings is the TULSA-PRO® technology, which combines cutting-edge MRI technology, AI-enhanced planning, and robotically-assisted ultrasound to facilitate precise treatment.
The TULSA procedure is designed to be a minimally invasive approach that combines effectiveness with patient comfort. Patients benefit from real-time MRI guidance, which ensures utmost accuracy while maintaining urinary continence and sexual function with a procedure that smoothly elevates targeted tissue temperatures without the need for incisions or radiation.
Innovative Medical Solutions Offered by Profound
In addition to TULSA-PRO®, Profound is also advancing its Sonalleve® therapeutic platform, which has gained CE marking for treating uterine fibroids and managing palliative pain from bone metastases. With FDA approval under a Humanitarian Device Exemption, Sonalleve® holds promise for various indications, presenting opportunities for its use in non-invasive ablation of abdominal cancers and hyperthermia treatments.
As the company continues to innovate, it is actively exploring additional potential treatments, underscoring its commitment to enhancing patient care.
Contact Profound for Further Details
For additional information or inquiries regarding Profound Medical, interested parties can reach out to:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Frequently Asked Questions
What is the significance of the upcoming financial results?
The financial results reflect Profound Medical's performance and provide stakeholders with insights into its business progress and future projections.
What technologies does Profound Medical offer?
Profound Medical develops advanced technologies such as TULSA-PRO® and Sonalleve® aimed at treating a variety of medical conditions with incision-free solutions.
How can investors participate in the conference call?
Investors can register for the conference call through the company's website to gain insights directly from the management team.
What are the benefits of TULSA-PRO®?
TULSA-PRO® offers a precision treatment that preserves critical functions while effectively abating diseased prostate tissue through a one-time, short procedure.
How is Sonalleve® utilized in treatment?
Sonalleve® is administered for non-invasive treatments of uterine fibroids and pain relief for bone metastases, showcasing the versatility of Profound’s technologies.
